Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples